SEATTLE--(BUSINESS WIRE)--Research sponsored by Somnus Therapeutics, Inc. demonstrates that new controlled-release formulations of a marketed insomnia medication have shown a pharmacodynamic profile indicative of a potential therapy that could address a frequent complaint of insomnia sufferers: preventing middle-of-the-night (MOTN) awakening without next-morning hangover.
